SUBSCRIBE
SUBSCRIBE
Tyler Patchen

Tyler Patchen

Freelance Writer

Tyler is a journalist with over six years of experience in the world of business journalism. He started his career with the Birmingham Business Journal in Birmingham, Alabama writing about health care, technology, sports business and education. He previously worked as a reporter for Endpoints News and for BioSpace, covering biopharma business and manufacturing. Tyler currently lives in Birmingham, Alabama and holds interests in reading, golf and is also a passionate sports fan. You can reach him at tpatchen94@gmail.com.

Pictured: 3D rendering of nerve cells and neurological disease
Drug Development
Sage’s Dalzanemdor Shows Effect in Huntington’s Study, Analysts Say Results ‘Underwhelming’
While Sage Therapeutics’ drug candidate showed a slight difference compared to placebo in a mid-stage Huntington’s disease trial, William Blair analysts in a Tuesday note to investors said they “remain cautious” on dalzanemdor and “do not view the small numerical changes as definitive.”
June 11, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: FDA sign at Washington D.C. headquarters
Drug Development
Adcomm Votes Unanimously for Lilly’s Alzheimer’s Treatment Donanemab
Despite concerns raised in FDA briefing documents about Eli Lilly’s Alzheimer’s treatment, donanemab, the committee concluded that the benefits outweighed the risks.
June 10, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Healthcare worker conducting an eye exam
Drug Development
Skye Nixes Eye Disease Drug After Phase II Failure, Focuses on Metabolic Program
Skye Bioscience is putting the kibosh on its SBI-100 candidate for glaucoma, and the company’s entire ophthalmology program, after a mid-stage study did not reach its primary endpoint.
June 10, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: The front entrance to the FDA headquarters/iStock, Grandbrothers
Drug Development
Biomea’s Stock Nosedives More Than 60% as FDA Puts Clinical Hold on Diabetes Candidate
Biomea Fusion’s early-stage investigational diabetes treatment BMF-291 has been slapped with a full FDA clinical hold on its Phase I/II trials due to concerns over liver toxicity.
June 7, 2024
 · 
1 min read
 · 
Tyler Patchen
Pictured: Photo illustration of hundred dollar bil
Drug Development
Structure Looks to Raise $476M in Upsized Public Offering After Positive Phase II Weight Loss Data
Structure Therapeutics is offering over nine million shares on the heels of mid-stage data for its oral GLP-1 receptor agonist, which showed weight loss of 6.2% in overweight or obese patients.
June 6, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: 3D image of liver damage/iStock,Mohammed
Drug Development
Gilead, Ipsen Tout Phase III Primary Biliary Cholangitis Data as PDUFA Dates Loom
Gilead Sciences’ primary biliary cholangitis candidate seladelpar and Ipsen’s PBC asset elafibranor both showed encouraging Phase III results Wednesday, as they face looming FDA decision dates.
June 5, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Illumina's headquarters in Silicon Valley
Deals
Illumina’s Board Votes to Spin Off Grail Instead of Selling Cancer Testing Firm
Illumina on Monday announced that its board of directors is spinning off Grail and has applied to list the cancer diagnostics company on the Nasdaq.
June 4, 2024
 · 
1 min read
 · 
Tyler Patchen
Pictured: Blood sample for Achondroplasia (FGFR3) 2 Mutation test to diagnose achondroplasia
Drug Development
BridgeBio Shows Positive Phase II Results in Treating Dwarfism Symptoms
BridgeBio’s oral small molecule infigratinib is proceeding with a late-stage study in children with achondroplasia after it improved body proportionality and height in children with dwarfism, the company announced Tuesday.
June 4, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: A blood sample of a patient tested positive for beta-thalassemia
Drug Development
Agios Blood Disorder Drug Scores Another Phase III Win
Agios Pharmaceuticals’ Pyrukynd met both the primary and secondary endpoints in patients with transfusion-dependent alpha- or beta-thalassemia.
June 3, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Woman carrying box of office things
Business
BIO24 Kicks Off in San Diego as City’s Biotech Hub Gets Hit with Jobs Downturn
While San Diego remains a top biotech hub behind Boston and San Francisco, the city—which hosts this week’s BIO International Convention—has seen employment drop amid economic headwinds.
June 3, 2024
 · 
5 min read
 · 
Tyler Patchen
Facade of the FDA's office in Maryland
Drug Development
FDA Delays Dupixent Uncontrolled COPD Decision as EU Panel Recommends Approval
Regeneron and Sanofi will have to wait until September 2024 for the FDA to decide whether to expand Dupixent’s label to include uncontrolled chronic obstructive pulmonary disease.
May 31, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Gilead's headquarters in Silicon Valley/
Drug Development
Gilead’s Trodelvy Fails to Reach Primary Endpoint in Confirmatory Trial
In addition to missing the mark in overall survival, Gilead reported Thursday a higher number of deaths in the Trodelvy arm of the confirmatory metastatic urothelial cancer study.
May 31, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: 3D illustration of autoimmune disease/iS
Drug Development
Immunovant Shifts Focus to Other FcRn Inhibitor, Gives Rival Vyvgart Breathing Room
The Roivant spinout is shifting its attention away from batoclimab to anti-FcRn candidate IMVT-1402, which will target autoimmune disorders, while allowing argenx’s Myasthenia Gravis drug Vyvgart to maintain its lead position for now.
May 30, 2024
 · 
2 min read
 · 
Tyler Patchen
External view of AstraZeneca's production plant in Sweden
Drug Development
AstraZeneca Touts Early-Stage Results for Oral PCSK9 Inhibitor
AstraZeneca on Wednesday unveiled Phase I results for its PCSK9 inhibitor, acquired from Dogma Therapeutics in 2020, which when combined with a statin reduced LDL-C levels in patients with high “bad” cholesterol.
May 29, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Exterior of AstraZeneca's building in S
Business
How Realistic is AstraZeneca’s $80B Revenue Target by 2030?
AstraZeneca last week set another ambitious goal, this time with plans to nearly double its total revenue by the end of the decade. However, it’s easier said than done, according to analysts.
May 28, 2024
 · 
4 min read
 · 
Tyler Patchen
Load More